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ABSTRACT
Objective: The aim was to determine relative frequencies of acute leukemia 
immunophenotypes using commonly expressed markers and to describe the 
clinicopathological characteristics.
Design: This was a prospective cross-sectional study.
Setting: The study was based at Aga khan clinical laboratory department.
Subjects: One hundred and thirty two (132) consecutive blood and bone marrow 
specimens from patients suspected to have acute leukemia were analysed for 
cytomorphological characteristics and immunophenotyping. The clinical-pathological 
characteristics were also recorded. Immunological category was assigned using the 
EGIL criteria. 
Results: There were 88 AML and 42 ALL patients analysed for immunophenotypes. 
Only tw cases of biphenotypic leukemia were found. The commonest overall AML 
morphological sub-type was AML-M2, 26 (29.5%). Majority of ALL cases were B-cell 
immunological sub-type (96.6%). Early pre-B phenotype constituted 62.07% and 
Common B-cell ALL 37.93%. There were only 4 cases of T-cell ALL. Majority of patients 
presented with anaemia with a median hemoglobin of 7.5g/dl (range 2-15g/dl). The 
median platelet count was 55 (range 4-462 × 109/L). 
Conclusion: Immunophenotyping of acute leukemia is beneficial in accurate diagnosis 
of patients with these malignancies in this setup. T-cell ALL, AML-M6 and M7 are 
less frequent than what has been reported in most studies in Africa.
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INTRODUCTION
Hematological malignancies are becoming major 
causes of morbidity and mortality in all age groups. 
The Leukemias have been shown to be a major health 
problem over the years with an incidence that is on the 
rise (1). Part of the reason for increase in incidence is 
due to improved diagn≠≠osis that exists and increased 
awareness of the condition .Availability and invention 
of new diagnostic modalities such as molecular 
techniques, immunological techniques to confirm 
suspected cases of any hematological malignancy 
have also made diagnosis and therapeutics of these 
conditions easier(2). Acute leukemias have been re-
classified by the World Health Organization (WHO) 
and this supersedes the earlier FAB criteria (18-22). A 
basic principle of WHO system is that the classification 
of hematopoietic and lymphoid neoplasms should 
utilize not only morphological findings but also 
genetic, immunophenotypic, biologic and clinical 
features to define specific disease entities(4-5).
 Ensuring accuracy in diagnosis is always the 
first goal towards correct treatment for patients with 
leukemia. Further more, standardisation, validation 
and reproducibility in diagnostic techniques are 
essential as a way of quality assurance in the 
laboratory(6). However, in resource poor countries 
like Kenya, all the diagnostic modalities of leukemia 
are not available and therefore the prevalence of the 
various subtypes of acute leukemia (AL) is not known. 
There is paucity of data on the prevalence of the various 
subtypes and immunophenotypic characteristics of 
the acute leukemia in Kenya. The authors sought 
to characterize the immunophenotypic profiles 
of acute leukemia and their clinical –pathological 
characteristics in all age groups.
MATERIALS AND METHODS
The study was carried out between June 2009 and 
August 2010. The aim was to determine relative 
frequencies of acute leukemia immunophenotypes 
using commonly expressed markers and to describe 
their clinicopathological characteristics. All cases of 
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confirmed acute leukemia by cytomorphology were 
eligible for inclusion. Cases of Chronic lympho/
myeloproliferative disorders, Myelodysplastic 
disorders, Acute leukemia with antecedent 
hematological malignancies and poor quality of 
bone marrow aspirate or peripheral blood film 
material that would make interpretation difficult(i.e. 
poorly preserved material resulting in hemolysis, 
clotting or freezing; use of formalin or other fixative; 
sample specimens showing degenerative changes) 
were all excluded. Cases of acute leukemia already 
on cytotoxic drugs and/or radiotherapy were also 
excluded.
 Bone marrow (BM) aspirates and blood 
films were assessed for cytomorphology. The 
pathological features were determined from full blood 
counts levels and this determined pancytopenia, 
leukocytosis, thrombocytopenia, and anemia. Bone 
marrow aspirates and peripheral blood films were 
stained with Leishman stain for morphological 
analysis. The morphological characteristics and 
cytochemical staining were reviewed independently 
to classify the acute leukemia according to the FAB 
criteria. Diagnostic interpretation and sub-typing 
as recommended by the FAB criteria was utilized. 
Clinical features (lymphadenopathy, splenomegaly, 
clinical CNS disease, hepatomegaly, anemia, bleeding-
included any petechiae, purpura, gum bleeding, 
epistaxis, per vaginal bleeding, gastrointestinal 
bleeding and hematuria) were recorded.
 Bone marrow and blood samples were 
immunophenotyped by using the multiparametric 
five-colour flow cytometer (Beckman Coulter FC 
500) , utilizing the panels of monoclonal antibodies 
using the European Group for the Immunological 
Characterization of Leukemia (EGIL) criteria. Cell 
suspensions were stained with multiple panels of 
three monoclonal antibodies and a two-step strategy 
was used, labeled with fluorescein isithiocyanate 
(FITC), Phycoerythrin (PE) and R-phycoerythrin-
Texas red (ECD) or Peridin chlorophyll Protein 
(PerCP). Cell suspensions were also stained with 
panels of identically conjugated isotype controls for 
the antibodies of each panel. Leukemic samples were 
considered positive for a particular antigen if 20% 
or more of leukemic cells reacted with a particular 
monoclonal antibody. Co- expression of the surface 
markers was analysed when antibodies of more than 
one lineage were present and scoring for bilineage 
undertaken using the EGIL criteria. The panels of 
antibodies included the following: CD34, HLA-DR, 
CD117, CD13, CD14, CD33, CD11c, CD19, CD10, 
CD20, cCD3, TdT, CD7, cMPO, sIg, CD15, CD56,CD45. 
The intracytoplasmic markers such as cCD3, cMPO, 
TdT and cIg antigens were evaluated by fluorescent 
conjugated monoclonal antibodies after fixation and 
permeabilisation of leukemic cells using IntraprepTM 
solution.
The cases were classified into six main ALL 
i m m u n o p h e n o t y p e s  a n d  e i g h t  A M L 
immunophenotypes. A case was considered pro-B 
ALL if it expressed (CD19+, CD34-,HLADR+,TdT 
-,lack of surface immunoglobulin),Pre B-ALL 
expressed same positive markers as pro-B ALL 
and (CD34+,TdT+,CD10+/- CD19+),Common 
B-ALL expressed similar positive markers with a 
high positivity for (CD10 ,CD19+,CD34-/+,and 
cytoplasmic and surface Ig).
 The T-cell ALL were considered when the 
markers for T-cell were positive i.e.,(cCD3+ 
,CD7+CD34+ ,TdT+,CD4- ,CD8-) as precursor T-cell 
ALL) and T-cell ALL with (cCD3+,CD7+,TdT+). 
Myeloid cases expressed progenitor antigens (HLA-
DR, CD7, CD34, CD117), as well as myeloid antigens 
(CD13, CD33, MPO), other myeloid lineage antigens 
(CD14, CD15) were found in more mature myeloid 
immunophenotypes.
Data Analysis: Data was analysed using SPSS version 
15.0. Patterns of categorical data (lymphadenopathy, 
haepatomegaly, Clinical CNS disease, and 
splenomegaly) were described graphically inform 
of tables and graphs.
 Analysis of Variance (ANOVA) was used to 
test the differences of hemoglobins, WBC, platelets 
count among the phenotypes. The association of 
immunophenotypes and the clinical pathological 
presentation was tested with Chi-Square test or 
Fishers exact test where numbers were below 5. A 
P-value of less than 0.05 was considered statistically 
significant.
RESULTS
There were 138 cases of acute leukemia as diagnosed 
morphologically out of which 132 were subjected to 
immunophenotyping. Six of the cases were rejected 
since they did not meet the inclusion criteria as 
outlined and specimen recollection was not feasible. 
Out of the 132 analysable specimens, 42 patients 
(31.8%) were less than fifteen years of age and 
classified as children, while 90 were adults (68.2%). 
These also comprised of 67(50.8%) males and 65 
(49.2%) females with M: F ratio of 1.03:1. The ages 
ranged from two years to 87 years with a median age 
of 29.5 years as seen in (Table 1). 
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Table 1
Demographic characteristics of patients 
Age category Male (%) Female (%) Total
Below 10 years 16 (55.2%) 13 (44.8%) 29
11-20 years 8 (40.0%) 12 (60.0%) 20
21-30 years 3 (15.0%) 17 (85.0%) 20
31-40 years 8 (40.0%) 12 (60.0%) 20
41-50 years 14 (70.0%) 6 (30.0%) 20
51-60 years 4 (66.7%) 2 (33.3%) 6
61-70 years 8 (88.9%) 1 (11.1%) 9
Above 70 years 6 (75.0%) 2 (25.0%) 8
Total 67 (50.8%) 65 (49.2%) 132
Eighty eight (67%) cases were acute myeloid leukemia 
and 42 (31.8%) were acute lymphoblastic leukemia. 
The peak age range for AML patients was 41-50 
years. There was a notable rise of AML cases from 
the 6th decade. There were 42 cases of ALL and two 
cases of biphenotypic leukemia (BAL). ALL was the 
commonest form of acute leukemia in young children 
with the relative frequencies reducing with age as 
illustrated in the bar graph in (Figure 1). 
Figure 1
Distribution of cases of Acute leukemia in different age categories (n=132)
The commonest AML in all patients was AML-M2 
accounting for 26 (29.5%) with 19 (21.6%) cases seen 
in adults and 7(7.95%) in children. The median age of 
adults with acute myeloid leukemias was 39.5 years 
(range 16-87). The peak age range for adult patients 
with the AML-M2 immunophenotype was 35 to 45 
years as shown. 
 Forty two cases were ALL and two cases were 
biphenotypic leukemia. Majority of ALL cases were 
seen in patients below 15 years of age and were of 
the B-cell phenotype 29 (69.04%) with the dominance 
of early pre-B phenotype at 62.07%, followed by 
Common B- ALL in 37.93% of patients ,while the T- cell 
ALL was seen in only one child. T-cell ALL (3 cases) 
were seen in adults. Only two cases of biphenotypic 
leukemias were seen in this series and were found 
in adults. 
 cMPO was the highest expressed cytoplasmic 
marker at 85.2% ,CD 117, CD13 and CD33 were 
the most commonly expressed surface markers for 
myeloid leukemia with 70.5% (95% CI: 60.3-79.7), 
81.8% (95% CI: 73.2-89.6) and 73.9 % (95% CI: 63.9-
82.6) positivity respectively. HLADR and CD34 
were also significantly expressed at 79.5% and 80.7% 
respectively. HLADR was negative in almost all the 
promyelocytic AML (aml-m3/v3) save for two cases 
which had dim positivity. CD7 (19.3%) and CD19 
(19.7%) were the most common aberrantly expressed 
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lymphoid markers on the myeloid blasts. CD11c and CD14 were the most commonly expressed markers for 
defining AML-M4/M5 as illustrated in (Table 2). 
Table 2






























cCD3 3 - 2 - - 1 - - 1 7 (7.9%)
CD5 3 - 3 - - - - - 1 7 (7.9%)
CD7 3 2 5 4 2 1 - - - 17(19.3%)
CD10 2 - 3 2 - - - - - 7 (7.9%)
CD11c 6 1 9 2 15 4 - - - 37(42%)
CD13 11 9 23 5 15 7 - - 2 72(81.8%)
CD14 4 1 7 3 14 4 - - - 33(37.5%)
CD15 - - 1 1 1 5 - - - 8 (9%)
CD19 4 0 4 3 5 1 - - 1 18(20.5%)
CD20 - - - - - - - - - -
CD33 6 8 21 8 14 6 - - 2 65(73.9%)
CD56 - - 1 - 4 1 - - - 6 (6.8%)
CD117 14 6 22 6 11 2 - - 1 62(70.5%)
TdT - - - - - - - - - -
HLADR 15 9 24 2 15 5 - - - 70(79.5%)
MPO 18 8 23 8 11 5 - - 2 75(85.2%)
CD45 18 9 26 9 17 6 - - 2 87(98.9%)
CD34 17 8 19 8 15 3 - - 1 71(80.7%)
CD 61/41 - - - - - - - - - -
CD235a - - 1 - - 1 - - - 2 (2.3%)
CD19 was the most expressed marker for B lymphoid leukemia (81.8% positivity). Other markers that were 
highly expressed in the B ALL phenotypes were HLADR, TDT, and CD10 with 93.2%, 77.5% and 77.3 % 
positivity. Overall, CD10 was expressed in 77.3% of cases and especially in B-ALL cases. CD7 was universally 
expressed in the T-ALL cases as well as cCD3 at 20.3 %;( 95%CI: 9.3-34.6).
CD13 and CD 33 were both aberrantly expressed in 20.5 % of the ALL cases as shown in (Table 3).
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Table 3
















cCD3 1 3 1 2 1 1 9 (20.3%)
CD5 0 4 2 2 2 2 12 (27.3%)
CD7 0 8 0 2 2 2 14 (31.8%)
CD10 0 17 14 0 1 2 34 (77.3%)
CD11c 0 1 0 0 0 0 1 (2.3%)
CD13 0 3 4 1 0 1 9 (20.5%)
CD14 0 1 1 0 0 1 3 (6.8%)
CD15 0 0 2 0 0 1 3 (6.8%)
CD19 1 20 15 0 0 0 36(81.8%)
CD20 0 5 5 0 0 1 11(25%)
CD33 0 4 3 1 0 1 9 (20.5%)
CD56 0 0 0 0 0 0 0 (0%)
CD117 0 0 0 0 0 1 1 (2.3%)
TdT 1 17 13 1 2 0 34(77.5%)
HLADR 1 20 15 2 1 2 41(93.2%)
cMPO 0 0 0 0 0 1 1 (2.3%)
CD45 2 21 15 2 2 2 44(100%)
CD34 1 11 4 1 0 2 19(43.2%)
Majority of the patients with acute leukemia presented with anemia as evident in the low hemoglobin median 
levels, 7.45g/dl (range 2-15g/dl); the median WBC count of 27 X 109/L (range 0.1-587) and platelets level 
of 55.1 X 109/l (range 4-462). The lowest median hemoglobin level was noted in AML-M2, while the lowest 
median platelets count was evident in AML-M3. 
AML-M3 showed the lowest median for WBC counts while the highest median was seen in AML-M2 as 
illustrated in (Table 4).
Table 4 




























23.1 (5 to 
82)
23.5 (1 to 
226)




27.0 (2 to 
192)





8.05 (3 to 
12)
6.8 (5 to 
15)
6.55 (4 to 
12)
8.5 (2 to 
11)
6.3 (3 to 
9)
9.5 (6 to 
12)
7.3 (4 to 
11)
0.135
Platelets 35 (7 to 
460)
39 (15 to 
104)








58 (20 to 
124)
0.041
Note: The Kruskal Wallis test was applied to establish the differences in median levels of WBC, Hb and 
platelet count across all the AML immunophenotypes).
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Thrombocytopenia was associated more with 
AML-M0 and AML-M3. The highest median WBC 
counts were seen in AML-M5 and AML-M4 while 
the lowest counts were seen in AML-M3.There was 
a significant difference in the medians of platelets 
counts across the immunophenotypes (P=0.041). In 
AML, the lowest hemoglobin was seen in patients with 
AML-M3V at 6.3 g/dl (range 3 to 9 g/dl) as shown. 
The lowest median hemoglobin was seen in Pre B 
common ALL and was 5.8 g/dl (range 3 to 10 g/dl). 
Thrombocytopenia was more associated with Pro 
B-ALL with a median platelets level of 18(range15 
to 21 × 109/l). The highest median WBC counts were 
seen amongst the Pre T-cell ALL patients 44.2 (range 
2 to 86 × 109/l). There was no significant difference 
in the clinical and hematological parameters across 
various ALL immunophenotypes.
DISCUSSION
This work gives the largest series of acute leukemias 
in Kenya providing data on immunophenotypic 
distribution of acute leukemias in adults and children. 
The five color flowcytometric immunophenotyping 
in this study pioneered use of the technique for acute 
leukemia in Kenya. The study comprised of 67(50.8%) 
males and 65 (49.2%) females with M: F ratio of 1.03:1. 
Acute leukemias have been shown to occur at equal 
frequencies in males and females in Sub-Saharan 
Africa probably indicating the etiological causes to 
be associated with common environmental factors 
(7-9). The age ranged from two years to 87 years with 
a median age of 29.5 years. 
 The commonest AML immunophenotype in all 
patients was AML-M2 accounting for 26 (29.5%) cases 
with 19 (21.5%) cases seen in adults and 7(7.95%) in 
children which is slightly higher than the frequency 
of 27-29% reported in the literature in all age groups. 
Advani et al has also observed a higher frequency of 
AML-M2 in both pediatric and adult population in 
India(15). The proportion of AML-M4 in this study 
was 19.3%. This falls in the same frequency as 16-25% 
reported in the literature. The incidence of AML-M3 
in this study was 12.5% and was slightly higher 
than reported frequency in the literature at 5-10%. 
An immunoprofile of CD34-, HLADR-, CD14- and 
CD33+ strongly favored AML-M3, as was seen in our 
patients. AML is a genetically and phenotypically 
heterogenous disease and these findings could just 
be due to the different spectrum of mutations that has 
occurred in this population of patients and the effect 
of other factors involved in leukemogenesis. Future 
studies involving cytogenetics and molecular analysis 
to determine if any differences at the molecular levels 
in our patients exist should be carried out. There were 
no cases of AML-M6 yet a frequency of 3-5% has 
been reported in the literature. There was no case of 
AML-M7 in this study. Generally, this would imply 
that the AML-M6 and AML-M7 are of low frequency 
and the study would need a higher number of patients 
to document them even if they are of low frequency.
Majority of cases were B-ALL at 29(96.6%) with 
the dominance of early pre-B phenotype in 62.07%, 
followed by Common B- ALL in 37.93%. Majority of 
ALL cases were seen in children<15 years and were 
of the B-cell phenotype 29 (69.04%), while the T- cell 
ALL was seen in only one child.
 There was a close association between T-cell 
phenotype with older age and higher leukocyte count, 
however, the cases were very few (four cases) to make 
any statistical inferences. The marked preponderance 
of childhood B-ALL in our series is, at least partly, 
attributable to the age distribution of the population 
and the general view that ALL is a disease of children 
and so these results were expected.
 The majority of patients presented with anaemia 
in this study with the median hemoglobin of 7.45g/dl 
(range 2-15 g/dl). Bleeding was most commonly seen 
in the promyelocytic and the monocytic leukemia. 
The median platelet count level in this study was 
 55.1 (range 4-462 × 109/L). This indicates generally 
that patients in this series had low platelets levels 
hence the high rate of anaemia and bleeding observed. 
Although lymphadenopathy is not often seen in AML 
this was present in 9% of the cases in this study. It 
is possible that patients could have had coexisting 
viral and mycobacterial infections presenting with 
adenopathy and a high index of suspicion for AML 
was needed.  However, as expected there were more 
cases of ALL presenting with adenopathy at 75% 
compared to those seen in AML.The phenotype 
associated with most cases of adenopathy was the 
Pre B-cell ALL but this was not statistically significant 
(P=0.193). Dakka et al has reported the presence of 
splenomegaly in >60% of his cases with ALL(11). In 
this study, however, splenomegaly was seen in 34% of 
patients with AML, a rate lower than in some studies 
in literature. In ALL, splenomegaly was noted in 12 
(27.7%) of cases (p = 0.381).The low frequency in 
this study could be due to the fact that none of the 
patients were subjected to radiological investigation 
for splenomegaly or hepatomegaly.
In conclusion, the relative frequencies of the 
immunological subtypes in this study are similar 
to that reported by most researchers in the world, 
except for the low frequency of T-ALL, AML-M6 and 
AML-M7. This study utilized flow cytometry to make 
a diagnosis of acute leukemia, a technology that has 
not been utilized here before. Immunophenotyping 
of acute leukemia is beneficial in accurate diagnosis 
of these malignancies in this setup and routine use 
of immunological typing would be recommended to 
benefit both the patients and clinicians.
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